13 completed, 6 terminated, 3 unknown, 1 recruiting. 23 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 13, Terminated 6, Unknown 3, Recruiting 1 |
| Phase 2 | 5 | Terminated 3, Recruiting 1, Unknown 1 |
Follow Clostridium Difficile Infection: new trials by email Literature Review of Clostridium Difficile Infection trials Research Report on Clostridium Difficile Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients Vancomycin 125mg, Placebo - Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection | Phase 2 / Phase 3 | Recruiting | Riverside University Health System Medical Center | 176 | 2024-10-21 | 2025-11-10 |
| Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection Fecal filtrate transplantation, Conventional fecal microbiota transplantation - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 3 | Unknown | University of Pecs | 238 | 2023-11-01 | 2023-05-19 |
| Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection Vancomycin, Placebos - Clostridium Difficile Infection | Phase 3 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 263 | 2020-11-19 | 2025-12-10 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) RBX2660 - Clostridium Difficile Infection, Infection | Phase 3 | Completed | Rebiotix Inc. | 793 | 2019-07-30 | 2024-08-07 |
| Fecal Transplantation for Primary Clostridium Difficile Infection Fecal microbiota transplantation, Vancomycin - Clostridium Difficile Infection | Phase 3 | Terminated | Oslo University Hospital | 104 | 2019-07-17 | 2024-09-19 |
| Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH) Fecal Microbiota Therapy (FMT), Placebo - Clostridium Difficile Infection | Phase 2 / Phase 3 | Terminated | VA Office of Research and Development | 153 | 2018-11-15 | 2024-04-11 |
| Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD) - Clostridium Difficile Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 148 | 2018-03-27 | 2023-07-27 |
| ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection SER-109, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Seres Therapeutics, Inc. | 182 | 2017-07-10 | 2023-04-27 |
| Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) Cadazolid, Vancomycin capsule, Vancomycin solution - Clostridium Difficile Infection | Phase 2 / Phase 3 | Terminated | Actelion | 1 | 2017-04-14 | 2025-07-08 |
| Clostridium Difficile Vaccine Efficacy Trial Clostridium difficile vaccine, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Pfizer | 17535 | 2017-03-29 | 2023-02-13 |
| Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection Fecal Microbiota, vancomycin, Loperamide - Clostridium Difficile Infection | Phase 2 / Phase 3 | Unknown | Queen Elizabeth II Health Sciences Centre | 50 | 2016-12-01 | 2016-09-27 |
| Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection Fecal microbiota transplantation, Fidaxomicin, Vancomycin - Clostridium Difficile Infection | Phase 3 | Completed | University of Aarhus | 64 | 2016-04-01 | 2019-10-15 |
| Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection Fidaxomicin - Clostridium Difficile Infection | Phase 3 | Terminated | McMaster University | 31 | 2015-07-01 | 2023-03-24 |
| IMT for Primary Clostridium Difficile Infection Intestinal microbiota therapy, Metronidazole - Clostridium Difficile Infection | Phase 2 / Phase 3 | Terminated | Oslo University Hospital | 21 | 2015-02-22 | 2020-09-22 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection | Phase 3 | Completed | Actelion | 632 | 2014-03-27 | 2025-02-04 |
| Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea Cadazolid, Vancomycin, Cadazolid-matching placebo - Clostridium Difficile Infection | Phase 3 | Completed | Actelion | 631 | 2013-12-12 | 2025-02-04 |
| Transplantation of Fecal Microbiota for Clostridium Difficile Infection Fecal Microbiota transplantation. - Clostridium Difficile Infection | Phase 3 | Unknown | Tel-Aviv Sourasky Medical Center | 10 | 2013-11-01 | 2013-10-09 |
| Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection C. difficile Toxoid Vaccine, Placebo: 0.9% normal saline - Clostridium Difficile Infection | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 9302 | 2013-07-30 | 2022-03-28 |
| Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) Surotomycin, Vancomycin, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 606 | 2012-05-16 | 2019-07-23 |
| A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) CB-183,315, Vancomycin, Placebo - Clostridium Difficile Infection | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 608 | 2012-05-16 | 2022-08-22 |
Showing 20 of 23. Sign in to see all of them.
Clostridium Infections (23) · Diarrhea (6) · Communicable Diseases (2) · Infections (2) · Enterocolitis, Pseudomembranous (1) · Gastroenteritis (1) · Recurrence (1) · Reinfection (1)
Bacterial Infections (23) · Bacterial Infections and Mycoses (23) · Gram-Positive Bacterial Infections (23) · Infections (21) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (6) · Signs and Symptoms, Digestive (6) · Disease Attributes (4) · Pathologic Processes (4) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Enterocolitis (1) · Gastroenteritis (1) · Intestinal Diseases (1) · Recurrence (1)
Vancomycin (10) · Fecal Microbiota Transplantation (4) · bezlotoxumab (3) · cadazolid (3) · CB-183,315 (2) · Fidaxomicin (2) · Metronidazole (2) · Loperamide (1) · Saline Solution (1) · actoxumab (1)
Actelion (3) · Merck Sharp & Dohme LLC (3) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Oslo University Hospital (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · McMaster University (1) · Pfizer (1) · Queen Elizabeth II Health Sciences Centre (1) · Rebiotix Inc. (1) · Riverside University Health System Medical Center (1) · Sanofi Pasteur, a Sanofi Company (1) · Seres Therapeutics, Inc. (1) · St Marina University Hospital, Varna, Bulgaria (1) · Tel-Aviv Sourasky Medical Center (1) · University of Aarhus (1)
United States (8) · Canada (7) · Hungary (4) · Poland (4) · Spain (4) · Colombia (3) · Czechia (3) · Germany (3) · Norway (3) · Sweden (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2)
Anne Claire Marrast, MD (2) · Aasma Shaukat, MD MPH (1) · Christine H Lee, MD (1) · Dimitri M Drekonja, MD (1) · Emily G McDonald, MD MSc (1) · Ian R Davis, MD,FRCPC (1) · Jens F Dahlerup, MD DrMSc (1) · Kjetil K Garborg, MD, Ph.d. (1) · Lisa von Moltke, MD (1) · Michael Bretthauer, MD, PhD (1) · Michael Bretthauer, Ph.d. (1) · Miglena I Georgieva, PhD (1) · Teena Chopra, M.D., M.P.H. (1)
PMID 28121498, PMID 29538686, PMID 29680101, PMID 29788418, PMID 30060024, PMID 30227108, PMID 30455246, PMID 30460321, PMID 30709665, PMID 31411386, PMID 31628838, PMID 32099847, PMID 32376702, PMID 32504314, PMID 32747931, PMID 36661328, PMID 24762631, PMID 27316794, PMID 28480267, PMID 28961905, PMID 30610862, PMID 31846705, PMID 31883370, PMID 32101275, PMID 32946836, PMID 33106983, PMID 34150673, PMID 34154439, PMID 35045228, PMID 35463939, PMID 36716031, PMID 36906440, PMID 37389891, PMID 38941068, PMID 39180325, PMID 39180326, PMID 39271107, PMID 40177588, PMID 40523286, PMID 40784972, PMID 41245385, PMID 41491103, PMID 41653256, PMID 41758514, PMID 42286373, PMID 42840322
2015 (1), 2016 (1), 2017 (1)